CM Life Sciences III Inc. (CMLT) Prices Upsized $480M IPO

CM Life Sciences III Inc. announced the pricing of its upsized $480 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “PANA”, Wednesday, April 7.

The new company aims to combine with a life sciences business with unique research tools, diagnostics, therapeutics, data, and industrial outputs. CM Life Sciences III is led by CEO Eli D. Casdin, Chairman Keith A. Meister, CFO and Secretary Brian Emes, and Chief Strategy Officer Shaun Rodriguez.

Total SPAC deal count for 2021 year-to-date is now 300. This offering is expected to close on Friday April 9.

Jefferies LLC and Cowen and Company, LLC are serving as the joint book runners for the offering. White & Case LLP is serving as Issuer’s Counsel with Skadden, Arps, Slate, Meagher & Flom LLP serving as Underwriter’s Counsel. WithumSmith+Brown, PC serves as auditor. Continental Stock Transfer & Trust Company is acting as trustee.